Eli Lilly and Co. said on Monday it will invest an additional $1.6 billion at its two new manufacturing sites in Indiana, United States to support the manufacturing of its recently approved cancer drug, Jaypirca, among others.
The company’s total investment commitment in the facilities now stands at $3.7 billion, Eli Lilly said.